ALXO241115C20000
- 4.30
- 0.000.00%
ALX Oncology Newsroom
Press Release: ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer
Cantor Fitzgerald Reiterates Overweight on ALX Oncology Holdings
LifeSci Capital Maintains ALX Oncology(ALXO.US) With Hold Rating
ALX Oncology Highlights Promising Trial Results
Stifel Maintains ALX Oncology(ALXO.US) With Hold Rating, Maintains Target Price $3
Stifel Nicolaus Sticks to Its Hold Rating for ALX Oncology Holdings (ALXO)
Positive Outlook for ALX Oncology: Buy Rating Backed by Promising Clinical Data and Strong Financials
ALX Oncology GAAP EPS of -$0.58
Express News | ALX Oncology Holdings - Board Appointed Shelly Pinto as Co's Interim CFO
Express News | ALX Oncology Holdings - on Nov 5, Peter Garcia, CFO of Co Informed of His Resignation From His Position Effective Nov 8
ALX Oncology | 10-Q: Q3 2024 Earnings Report
Express News | ALX Oncology Q3 Net Income USD -30.707 Million
Express News | ALX Oncology Q3 Basic EPS USD -0.58
Press Release: ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
ALX Oncology Announces Results From Phase 1b/2 Trial of Evorpacept in Combination With Zanidatamab Will Be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
Express News | ALX Oncology Announces Results From Phase 1B/2 Trial of Evorpacept in Combination With Zanidatamab Will Be Presented at the San Antonio Breast Cancer Symposium (Sabcs) 2024
Millennium Management LLC Reduces Stake in ALX Oncology Holdings Inc
ALX Oncology CMO Sophia Randolph Announces Resignation
Catalyst Watch: Spotlight on Micron, Southwest Airlines, and FOMC Speakers
Global CD47 Inhibitor Drug Clinical Trials Insight & Market Opportunity Outlook to 2028 - ResearchAndMarkets.com